Skip to main content
Loading ResearchHub…
References for Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study | ResearchHub - ResearchHub